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Abstract
Background: A face-to-face survey of 158 policymakers and other influential professionals was conducted in eight dengue-
endemic countries in Asia (India, Sri Lanka, Thailand, Vietnam) and Latin America (Brazil, Colombia, Mexico, Nicaragua) to
provide an indication of the potential demand for dengue vaccination in endemic countries, and to anticipate their research
and other requirements in order to make decisions about the introduction of dengue vaccines. The study took place in
anticipation of the licensure of the first dengue vaccine in the next several years.
Methods/Principal Findings: Semi-structured interviews were conducted on an individual or small group basis with
government health officials, research scientists, medical association officers, vaccine producers, local-level health authorities,
and others considered to have a role in influencing decisions about dengue control and vaccines. Most informants across
countries considered dengue a priority disease and expressed interest in the public sector use of dengue vaccines, with a
major driver being the political pressure from the public and the medical community to control the disease. There was
interest in a vaccine that protects children as young as possible and that can fit into existing childhood immunization
schedules. Dengue vaccination in most countries surveyed will likely be targeted to high-risk areas and begin with routine
immunization of infants and young children, followed by catch-up campaigns for older age groups, as funding permits. Key
data requirements for decision-making were additional local dengue surveillance data, vaccine cost-effectiveness estimates,
post-marketing safety surveillance data and, in some countries vaccine safety and immunogenicity data in the local
population.
Conclusions/Significance: The lookout for the public sector use of dengue vaccines in the eight countries appears quite
favorable. Major determinants of whether and when countries will introduce dengue vaccines include whether WHO
recommends the vaccines, their price, the availability of external financing for lower income countries, and whether they
can be incorporated into countries’ routine immunization schedules.
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Introduction
Dengue, a mosquito-borne Flavivirus infection caused by four
related viruses (DENV1 to 4), is a major public health problem in
the tropics and subtropics. The greatest documented burden of
dengue occurs in Asia and Latin America. Dengue’s geographic
range now places an estimated 3.97 billion people at risk and it
continues to expand, causing epidemics that disrupt health care
systems [1,2]. The World Health Organization estimates that each
year there may be up to 50 million dengue infections worldwide
and 500,000 cases of dengue hemorrhagic fever (DHF) – a severe
form of the disease [3]. According to the 2010 Global Disease
Burden Study, dengue causes nearly 15,000 deaths per year, a
29% increase since 1990 [4].
Dengue vaccines have been under development since the 1940s,
but the vaccine industry’s interest in the vaccines languished
throughout most of the 20th century [5]. However, dengue vaccine
development has accelerated in recent years and several vaccine
candidates are in or near to human clinical development. The
most advanced is a recombinant live chimeric tetravalent vaccine
(CYD TDV) developed by Sanofi Pasteur [6], consisting of four
genetically engineered viruses in which several genes in a yellow
fever DNA backbone have been replaced with comparable genes
from the four dengue viruses. The vaccine is being evaluated in a
three-dose regimen given over a one-year period (at six month
intervals) in efficacy trials in multiple countries in Asia and Latin
America. Although this and all other dengue vaccines are intended
to be used with children and adults, initial licensure is likely to be
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limited to children 2–14 years of age, since the current clinical
trials are evaluating the vaccine in this age group.
Two other live attenuated chimeric dengue vaccine candidates
in are Phase II evaluations: one developed by the U.S. National
Institutes of Health [7], and another being developed by Inviragen
[8]. In addition, a recombinant subunit vaccine under develop-
ment by Merck has completed Phase I trials [9].
This survey of eight dengue-endemic countries in Asia and the
Americas was conducted by the Pediatric Dengue Vaccine
Initiative (PDVI), managed by the International Vaccine Institute,
to determine their possible interest in and perceived need for a
dengue vaccine; what factors (e.g., vaccine characteristics,
financing, political pressure, data needs) would drive or influence
decisions; and what strategies countries would likely use to target,
deliver and finance dengue vaccination. The main objectives of
the survey were to: 1) provide an indication to donors, vaccine
producers, and the international health community of the
potential interest in and demand for dengue vaccination from
endemic countries and what factors may affect this demand; and 2)
anticipate the research, disease surveillance and other require-
ments that countries will have in order to make decisions about the
introduction of dengue vaccines.
Surveys of policymakers and other stakeholders about new or
under-utilized vaccines have been used in the past to inform
research and advocacy activities of product development partner-
ships, including a multi-country study about rotavirus vaccines
[10] and a seven-country survey concerning cholera, typhoid fever
and shigellosis and vaccines against these diseases [11].
Methods
Country selection
The survey was conducted in four Asian countries (India, Sri
Lanka, Thailand and Vietnam) and four Latin American countries
(Brazil, Colombia, Mexico and Nicaragua). This was a conve-
nience sample of countries that are considered dengue-endemic
where PDVI had contacts viewed as reliable authorities on dengue
in their countries and who could facilitate arrangements for
interviews with policymakers. Several of the countries were viewed
by the investigators as potential early adopters of dengue vaccines
based on reports of dengue outbreaks and expressed concern from
health officials and the public about dengue in the country. No
country that was requested to participate in the study refused to do
so.
Data collection and selection of topics
The study consisted of face-to-face interviews conducted on an
individual or small group basis during country visits that took place
between September 2008 and December 2010. All policymakers
and other stakeholders interviewed consented to the interviews,
which were voluntary, and participants were informed that their
responses would be anonymous.
The interviews were semi-structured, using a question guide
consisting entirely of open-ended questions (Appendix 1). The
guide explored informants’ views and perceptions about:
N the magnitude and seriousness of dengue in their country, as
well as epidemiological patterns and trends;
N the level of priority of dengue control;
N the quality and accuracy of dengue surveillance data;
N the effectiveness of current dengue prevention and treatment
methods;
N the need for and interest in dengue vaccines;
N preferred attributes and criteria for dengue vaccines;
N required data to inform decisions about the introduction of
dengue vaccines; and
N strategies for vaccine introduction and use (including age and
geographical targeting, vaccine delivery methods and chan-
nels, and financing strategies).
The semi-structured interview approach was felt to be the most
appropriate for high-level informants, as opposed to a highly-
structured questionnaire. This format facilitated the free expres-
sion of opinions and ideas among informants, allowed for probing
and clarification of responses, and for the identification of new
issues and topics as they arose. All informants were asked a core set
of questions concerning their views about dengue, current prevent
and control measures, and various aspects about dengue vaccines,
while additional specific questions were asked to individuals,
according to their expertise and position. For example, immuni-
zation program officials were asked about government plans and
priorities for new vaccine introductions and vaccine producers
were asked about the status and plans of vaccine development.
The interviews were conducted in English by one or more of the
authors in each country. Local collaborators who arranged the
interviews and meetings, also sat in on several of them and served
as translators, as needed, in interviews conducted in the Latin
American countries.
Selection of interviewees (‘‘informants’’)
Persons to be interviewed in each country were identified based
on a list developed by PDVI of the types of organizations and
individuals to target. An effort was made to meet as many
individuals and groups as possible who potentially have a role in
making or influencing decisions about the future introduction of
dengue vaccines into national immunization programs, including
decision-makers within health ministries; chairs or members of
national immunization technical advisory groups (NITAGs);
immunization program heads; international aid agencies; leading
Author Summary
Information gleaned from surveys of country-level policy-
makers and other opinion leaders can assist in planning
the development, production and introduction of new or
upcoming vaccines into public sector immunization
programs. In the case of dengue vaccines, prevailing views
among these leaders about the importance of the disease,
their expressed level of interest in the government’s use of
the vaccine, and preferred strategies for vaccine introduc-
tion (e.g., geographically-targeted vs. nation-wide vacci-
nation, specific age groups to target) can help to identify
‘‘early adopter’’ countries and indicate the level of demand
for the vaccine. This information can be critical to current
producers of the vaccine in planning their production
capacity and to potential future producers in deciding
whether to pursue development of the vaccine. This
information also helps donors and international technical
agencies, such as WHO and UNICEF, in setting their
priorities and determining their level of technical and
financial support to countries for the introduction of
dengue vaccines. In addition, these surveys can provide
crucial information to national governments and the
above stakeholders about potential barriers to introducing
dengue vaccines into national immunization programs,
and what additional studies and data countries will require
in order to make decisions about use of the vaccines in the
public sector.
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scientists; national regulatory authorities; and local vaccine
producers. Efforts were also made to meet with the highest level
officials in each organization and category as possible. If people
who were suggested to be interviewed were not available or did
not respond, they or their office usually recommended a colleague
within the organization or department to interview.
As shown in Table 1, those interviewed included senior officials
from ministries of health (MOHs) (e.g., Directors General of
Health Services, health secretaries and directors of communicable
diseases) and other government health agencies (e.g., centers for
disease control, national regulatory authorities, national health
insurance agencies). They also included national immunization
program managers (in five countries); and MOH officials and
scientists from dengue control and vector control programs,
disease surveillance and epidemiology, infectious disease control
and planning departments. Other informants included officials
and scientists from public and private research institutes and
academic institutions; top officials of major hospitals; officers of
medical associations; health authorities at the regional, state and/
or municipal level (including state or provincial health ministers or
the equivalent and chief medical officers); officials from interna-
tional technical agencies (e.g., WHO, UNICEF); and representa-
tives from local vaccine producers (in India, Vietnam, Brazil and
Mexico) or multi-national pharmaceutical companies (in Colom-
bia). Several of those interviewed also served on their country’s
NITAG.
Between 14 and 32 persons took part in the interviews in each
country, for a total of 158 individuals (average of <20 per
country).
Data analysis
The results were analyzed separately for each country.
Extensive notes were taken for each interview and a complete
set of notes were transcribed by topic area and then by person or
group interviewed, including salient quotations. From these
transcripts, the types and patterns of responses were analyzed by
the type and level of informants. Responses were reported if at
least two persons in a country gave a similar response. Individual
country reports were then prepared that included sections on
perceptions about the importance and priority of dengue in the
country; perceptions about current dengue prevention and
control; the perceived need for dengue vaccines; concerns, criteria
and data needs regarding dengue vaccines; and possible vaccine
introduction strategies and scenarios. Both the raw data (interview
notes) and country reports were used in preparing this manuscript.
Results
Perceived importance and priority of dengue
The majority of policymakers, hospital directors, and other
informants whose work is not focused solely on dengue considered
dengue an important disease and a priority in all eight countries
included in the study. The disease was called a ‘‘major public
health problem’’ by a senior health official in India, and ‘‘right at
the top’’ [of health priorities] by a senior MOH official in Sri
Lanka. Dengue was deemed ‘‘unappreciated by donors and the
government’’ by preventive medicine officials and NITAG
members in Vietnam. Similarly, senior health policymakers in
Colombia described the disease as a ‘‘very high priority’’ and
‘‘very important’’ in terms of hospitalization and loss of
productivity. In Brazil, the chair of the country’s NITAG
described dengue as one of only two diseases without effective
control (the other being leishmaniasis) and considered it a high
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Nicaragua, dengue was described by a senior Ministry of Health
official as not normally one of the top 20 priority diseases, but
when there is an outbreak, it rises to the top and becomes the
number one priority.
The disease is especially a high priority among those on the
frontlines of dengue prevention and control. City health officials in
Colombo, Sri Lanka ranked dengue their number one disease
priority, and it is the only disease which the city government tracks
through GIS mapping. City health officials also keep a map
showing all cases of the disease on a large poster board (along with
leptospirosis) that is updated daily.
Agreement among policymakers and other informants about the
importance of dengue was not universal, however. A senior health
official in India did not consider dengue a top priority like malaria,
while some hospital officials in the country believe that the
extensive media attention given to dengue outbreaks takes the
focus away from other important endemic diseases, such as
diarrhea, enteric fevers and hepatitis. And according to some
hospital officials in Thailand, dengue is now less recognized by
politicians as a major problem due to the country’s success in
reducing dengue shock syndrome (DSS) and deaths to a low level.
The main reasons why informants considered dengue a priority
disease are the following:
N The disease is spreading within countries and is no
longer confined to cities
This was a key factor mentioned by informants in all countries
except Colombia and Nicaragua (where dengue is still largely
considered an urban disease). According to interviewees in Sri
Lanka, for instance, dengue was mainly confined to the city of
Colombo in 1996, but by 2004 it had spread to 10 districts, and by
2007 to nearly all of the country’s 26 districts. In Vietnam, where
dengue has been endemic in the South for decades, outbreaks
occurred in the North of the country in 2008 for the first time. The
spread of the disease to peri-urban and even rural areas was a
common perception and concern among informants in India, Sri
Lanka, Vietnam, Thailand, Brazil, and Mexico, which they
attribute to increased development of these areas, leading to
building construction, proliferation of garbage, open water storage
and other conditions favorable to the breeding of dengue-carrying
mosquitoes. According to one informant in Brazil, 40% of dengue
cases reported since 2007 have come from the outskirts of large
cities. Some informants in Vietnam, Thailand and India believed
that dengue is considerably more under-reported in rural areas
than in cities and that the incidence could be as great in rural areas
as in urban areas.
N Growing incidence and increased frequency of major
outbreaks
Informants in several countries, including Sri Lanka, Thailand
and Nicaragua, report an increase in dengue incidence over the
past several years. Those in the Asian countries of Sri Lanka,
Vietnam, Thailand report that major outbreaks are now occurring
every year, while as recently as five or six years earlier, they used to
occur every three or four years, The disease was described in Sri
Lanka as changing from an epidemic disease to a ‘‘hyper-
endemic’’ disease that occurs throughout the year.
N The epidemic pattern of the disease, overwhelming
hospitals and causing fear and panic in the population
According to dengue researchers in Brazil, dengue overwhelms
the health care system in urban areas during outbreaks more than
any other disease, in terms of its numbers and severity. Informants
in other countries report a similar phenomenon. During a major
outbreak in Delhi, India in 2006, dengue wards were set up in
tents outside of a major hospital, where 1,200 cases were treated
daily. Dengue cases make up thirty to forty percent of all pediatric
patients at a provincial hospital in Thailand during outbreaks. And
at a national children’s hospital in Managua, Nicaragua, the
number of beds was increased 64% during an outbreak in 2009,
mainly to accommodate dengue patients. The burden placed on
hospitals during dengue outbreaks is increased even more by the
panic that strikes the public, according to informants in Sri Lanka
and Brazil. One expert in Sri Lanka describe ‘‘dengue phobia’’,
which causes parents to rush their child to a health facility at the
first sign of a fever, fearing that it’s dengue.
N The highly visible and political nature of the disease
Because dengue occurs in outbreaks and urban populations are
affected, it garners considerable media attention, placing pressure
on politicians – especially at the local level – to find a way of
controlling the disease. According to one informant in Thailand,
whenever a child dies of dengue, it is reported in the media. Given
this visibility, there can be high costs to political leaders viewed as
failing to control outbreaks. In Brazil, mayors as well as officials
responsible for vector control have been replaced because of
dengue outbreaks, according to informants. Outbreaks in
Colombia have prompted political leaders to declare a state of
emergency, as occurred in Cali in 2010 after more than 1,200
cases and nine deaths were reported.
N The rapid onset of severe symptoms
Informants in both Asian and Latin American countries (India,
Thailand, Nicaragua) gave as a major reason for dengue being a
priority the fear among physicians of an otherwise healthy, well-
nourished child deteriorating in a matter of hours, leading to DSS,
other complications, and even death. As one hospital director in
Thailand stated, ‘‘Death due to dengue is particularly tragic,
because children go from healthy to fatal very rapidly.’’ The speed
at which complications developed during a major dengue outbreak
in Managua, Nicaragua in 2008 took medical experts and hospital
officials by surprise; even within the first day of the onset of
symptoms, patients were developing severe symptoms, including
circulatory shock. However, informants in Thailand and Vietnam
pointed out that rates of DSS and dengue-associated deaths have
remained the same or have even decreased in the past decade or
so, due to early and more effective treatment.
N Shifts in the age patterns of the disease
Dengue has been viewed as mainly a children’s disease in Asia
and as an adult disease in Latin America. However, in some Latin
American countries, notably Brazil, children are increasingly being
affected by the disease, causing concern in the medical and public
health community. A dramatic shift in DHF cases from adults to
children occurred in Brazil in 2007 [12], which informants claim is
responsible for the increased severity of the disease in the country.
N The economic impact of dengue on government
budgets
Informants interviewed in all countries except India gave the
economic impact of dengue as a reason for their concern about the
disease. In Colombo, Sri Lanka, 20% of the city government’s
entire health budget – which covers the cost of health clinics,
maternity homes, water quality and many other activities – is spent
Dengue Vaccine Policymaker Survey
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on dengue-related activities. Officials in one province in Nicaragua
estimated that dengue control efforts during outbreaks typically
consume 60% of the province’s emergency budget. Hospital costs
during dengue outbreaks can also put a severe strain on health
budgets, as reported in Mexico.
N Other factors
Another reason given in some countries for the perceived
growing importance of dengue is the great progress made in
controlling or reducing mortality from other major infectious
diseases at the same time as dengue incidence is increasing and/or
expanding geographically. In Sri Lanka, the control of tuberculosis
and malaria through intensive treatment, Japanese encephalitis
(JE) through vaccination, and diarrheal disease deaths through
oral rehydration therapy has reduced the relative importance of
these diseases among policymakers, resulting in dengue rising to
the top of infectious disease priorities. Similarly, in Nicaragua,
informants pointed out that malaria and several other diseases
(measles, rubella) have largely been brought under control in
recent years, while little progress has been made on dengue.
A further reason for the sense of priority of dengue among
informants, as mentioned in Thailand, Brazil and Nicaragua, is
the fact that the disease strikes all sectors of society – rich and poor
alike – and thus no one is immune from getting the disease.
The level of interest in dengue vaccines among
policymakers and opinion leaders
Interest among policymakers and opinion leaders in the public
sector use of dengue vaccine was on the whole quite high – though
not universal – in the eight countries surveyed. A senior MOH
official in Sri Lanka, where interest in dengue vaccines was
universally high amongst those interviewed, believed that the
government would introduce a dengue vaccine if it was affordable,
even in the absence of donor funding. Similarly, a health policy
expert in Mexico claimed that a dengue vaccine would be
accorded a ‘‘high priority’’ by the government once one becomes
available. And according to a high-level health ministry official in
Nicaragua, the government would have a ‘‘genuine interest in
making a [dengue] vaccine available to the population that needs
it most.’’ A provincial health official in the country claimed that
the introduction of a dengue vaccine would be ‘‘a priceless
achievement in public health’’, saving the country, the health
system and people money.
Government officials in India were more hesitant to state an
interest by the government in using dengue vaccines, in the
absence of data about their safety and performance. A senior
health official was skeptical of the need for the vaccine, claiming
that vector control is preferable to a vaccine and is succeeding.
However, expressed interest in dengue vaccines in India was high
among non-government informants on the frontline of treating
dengue cases, such as hospital officials and representatives of
professional medical associations.
According to interviewees in several countries (Sri Lanka, India,
Thailand, Brazil, Mexico), a key driver of government interest in
dengue vaccines is the great pressure that the public and in some
cases, the media will put on the government to introduce the
vaccines, once available. The high expected public demand is due
to the outbreak pattern of the disease, the media attention that it
attracts, the public’s high awareness of the disease in these
countries, and the fear that it engenders in the population. In
Thailand, interviewees believed that such pressure would result
from the inequities created by having a dengue vaccine available
in the private market but not through the national immunization
program for free. Pressure would also come from the medical
community in many countries, given the lack of specific treatment
for dengue and the difficulty in predicting its course. According to
several informants in Sri Lanka, such population demand, coupled
with media pressure, is a stronger driver of new vaccine
introductions than evidence of disease burden or cost-effectiveness,
since politicians ‘‘are sensitive to population demand’’. An official
from an Indian vaccine producer, in fact, described vaccines
against dengue and Japanese encephalitis (JE) as ‘‘political
vaccines’’, given the public’s tendency to blame politicians for
outbreaks of these vector-borne diseases in their community. The
potential political benefits of introducing a dengue vaccine is
described by a health policy expert in Mexico: ‘‘A courageous and
early decision taken about dengue vaccines by the next govern-
ment could be an early win for [them]. Launching a dengue
vaccine to coincide with the political cycle could be most helpful.’’
Despite the generally high level of interest in dengue vaccines
expressed by most informants in the eight countries, several,
including government officials in India, Thailand, Mexico and
Nicaragua, were more cautious about embracing vaccines whose
safety, performance and cost are not yet known. According to
these informants, questions about a dengue vaccine’s safety, the
number of doses required, its effectiveness and duration of
protection, as well as its affordability and financing, would have
to be answered before their government would use it in the public
sector. As one provincial government official from Nicaragua
stated, ‘‘It is important not to raise unrealistic public expectations
about dengue vaccines and their ability to stop infections soon
after introduction.’’ The relatively low mortality of the disease
could also be an obstacle to its rapid introduction into government
immunization programs, according to some informants. As one
informant in Mexico declared, ‘‘The government would need to
be convinced of the importance of making large budget allocations
for dengue vaccines, since there are only around 2,000 cases of
DHF and 20 deaths per year.’’
Concerns, criteria and preferences regarding dengue
vaccines
The top concerns that informants had about dengue vaccines
were their safety, cost and whether they can be used in infancy or
early childhood.
Safety. Safety concerns centered around three main issues:
1) Whether the vaccine can lead to enhanced disease since
previous dengue infections increase the risk of severe disease
from subsequent infections with different dengue serotypes
[13]. Informants were concerned that such cross-enhance-
ment could develop in people exposed to the disease before
they receive all vaccine doses or if the vaccine does not confer
long-lasting protective antibodies against all four dengue
serotypes;
2) Whether there will be interference between dengue and JE
antibodies induced by either natural JE infection or by JE
vaccination (raised by informants in Sri Lanka and Thailand);
3) Whether live vaccines could convert to virulence or could
introduce a new serotype into a country.
Vaccine cost. According to those interviewed, the price of
dengue vaccines to the public sector would be a major determinant
of whether or not governments would introduce the vaccine (as
mentioned in India and Colombia), how widespread its introduc-
tion would be (Mexico, Vietnam), or whether introduction would
be delayed (Thailand). Most informants would not give a
maximum acceptable price of the vaccine for the public sector,
Dengue Vaccine Policymaker Survey
PLOS Neglected Tropical Diseases | www.plosntds.org 5 March 2013 | Volume 7 | Issue 3 | e2127
but those that did gave thresholds reflective of their country’s
income level. A Thai official suggested that a price of less than $10
a dose would be acceptable, while the maximum acceptable price
given by Mexican informants ranged from less than $10 to $15 per
dose. A university health economist in Colombia who conducts
economic analyses of new vaccines felt that full introduction would
take a long time unless the vaccine costs no more than $5.00 per
dose. In the much poorer country of Vietnam, one MOH official
believed that $5 per dose was much too expensive, while another
gave a preferred price of $1 per dose.
Minimum age of effectiveness and vaccination
schedule. There was a strong preference expressed among
informants in all countries for a dengue vaccine that protects
children as young as possible – that is before they are exposed to
any of the four dengue viruses. Policymakers also strongly
preferred a vaccine that would fit into their existing routine child
immunization schedule. When asked about the acceptability of a
vaccine that cannot be given until the age of one – the likely
minimum age at which live attenuated dengue vaccines can be
given due to interference from circulating maternal antibodies in
infants – informants in most countries considered a schedule that
starts at 12 months of age (or 9–12 months) acceptable. This is in
part because many countries in the study have extended their
immunization schedule to the second year of life and beyond, as
they introduce new vaccines not given to infants (e.g., JE, human
papillomavirus (HPV)), and add booster doses of other routine
vaccines (e.g., DTP, OPV) to the schedule. In Sri Lanka, for
example, there are now five contacts in the immunization schedule
from the age of one to school entry.
A dengue vaccine requiring two doses was viewed as acceptable
by most informants across countries. However, a three-dose
regimen was considered a problem in India – because of
significant dropout rates in the country – as well as in Brazil.
Few interviewees would state specific thresholds of acceptable
efficacy rates for a dengue vaccine. Some in Vietnam and India
felt that the vaccine should be at least 90% protective, while others
in Vietnam would accept rates as low as 80–85% or even 70%. A
senior academic and NITAG member in Sri Lanka would accept a
vaccine that is at least 50% efficacious.
Other criteria. A WHO recommendation for the use of
dengue vaccines was cited as an important criterion for
introduction into public sector programs by several informants
in Vietnam, Thailand and India. According to interviewees in
Nicaragua and Colombia, WHO pre-qualification of the vaccine
would also be required before it could be introduced into their
national immunization program.
Possible strategies for dengue vaccine introduction
Scope of vaccination. Informants in Sri Lanka and Thailand
believed that dengue vaccine introduction in their countries would
be nation-wide, since the disease is considered endemic through-
out both countries. However, it could be rolled out in a few
provinces initially to demonstrate the vaccine’s effectiveness,
determine the best strategies for implementation, and work out
logistical challenges. There was also preference for nation-wide
introduction of the vaccine among informants in Nicaragua.
However, in the remaining five countries, most informants
discussed targeting high-risk areas initially, with the possibility of
eventual introduction nation-wide, if funding is available, the price
of the vaccine – assumed to be high initially – is reduced to
affordable levels, and the vaccine supply is sufficient. According to
some interviewees in Mexico, if dengue vaccines are initially very
expensive, it could still be introduced quite early after its entry into
the market, but on a very limited basis municipality by
municipality, based on an analysis of disease incidence. Some
Mexican informants would also prioritize tourist areas, such as
Monterey, Cancun and Acapulco, to protect the ‘‘national image’’
and the important tourism industry.
In both Mexico and Colombia, informants raised the possibility
of local governments introducing and financing the vaccine on
their own before it is adopted by the national immunization
program. There is precedent for this in Colombia, where the city
of Bogota had purchased some new vaccines, including pneumo-
coccal conjugate and hepatitis A, that were not yet available
through the national immunization program at the time of the
survey.
In India – where dengue is now considered endemic in 18 out of
the 35 states – two scenarios were proposed by various informants,
both beginning with the use of the vaccine in the private sector. In
one scenario, certain municipality and state governments would
introduce dengue vaccine with their own funding, due to the high
political costs that dengue outbreaks can exact on local politicians.
The other scenario would follow the model of JE vaccine
introduction: outbreaks would occur, creating outrage from the
public once they learn that a vaccine exists, leading affected states
to demand that the Universal Immunization Program (UIP)
provide the vaccine in high-risk areas.
Target ages and delivery strategies. Informants in all
countries believed that children would be the top priority for
dengue vaccination, beginning with the youngest ages eligible to
receive the vaccine, preferably through the routine immunization
schedule. As with geographic targeting, several countries would
phase in vaccination to other age groups, as the vaccine price
decreases and funding allows. According to informants in Brazil,
Mexico, Colombia and Thailand, pre-school and school-aged
children up to the age of 15 would next be targeted, likely through
school-based catch-up campaigns.
Expanding government-financed dengue vaccination to adults
was specifically mentioned only in Brazil, Colombia, and Mexico –
three Latin American countries where adults still account for a
substantial portion of the dengue disease burden. Several mass
vaccination campaigns that targeted a range of age groups were
given as potential models for dengue vaccine delivery in these
three countries. These include H1N1 influenza vaccination
campaigns for young children (e.g., 5–18 month olds), pregnant
women, and the elderly; and rubella elimination campaigns that
involved routine immunization for one year olds, follow-up
vaccination for pre-schoolers, catch-up campaigns for 1–14 year
olds, and one-time ‘‘speed-up campaigns’’ for adolescents and
adults.
Financing for dengue vaccination. There was general
agreement among informants in Vietnam and Nicaragua – both
GAVI-eligible countries – that GAVI or other donor financing
would be critical for the widespread or early introduction of a
dengue vaccine through the public sector. In Sri Lanka, which is
now graduating from GAVI support, not all agreed that donor
funding would be necessary for introduction of the vaccine into the
national immunization program, given the priority of dengue
within the government.
Dengue vaccine introduction into the national immunization
program will be financed by the federal government in Thailand,
Brazil, Mexico and Colombia – all middle-income countries that
are self-financing for vaccines. However, several informants in
these countries suggested that free dengue vaccination through the
national program could be limited to certain age groups (e.g.,
children under a certain age), while older children and/or adults
would have to get vaccinated in the private sector and be asked to
pay. In the case of Thailand, Colombia, and Mexico, these costs
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could potentially be covered, at least partially, by national health
insurance, social insurance or private insurance.
Source of dengue vaccines: local production vs.
importing. Five of the eight countries in the study – India,
Thailand, Vietnam, Brazil and Mexico – produce vaccines locally,
and dengue vaccines are currently in development in India,
Vietnam and Brazil, including the U.S. NIH chimeric vaccine
licensed to producers in all three countries.
According to several interviewees in Brazil, the government
would be willing to buy imported vaccine if locally-produced
dengue vaccine is not yet available, although probably only on a
small scale, since a high price is assumed. Thus, broad public
sector use of dengue vaccines in Brazil may have to wait until a
locally-produced vaccine is available in sufficient quantities. In
India, a dengue vaccine used by the UIP would likely have to be
produced locally or at least filled-finished in the country.
In Vietnam, according to informants, the likely steps that the
government would follow would be to initially import dengue
vaccine to avoid long delays in its use, then to fill-finish imported
bulk vaccine locally, and finally to produce the vaccine from
scratch through technology transfer. In Mexico, the possibility of
the government supplier, BIRMEX, fill-finishing imported bulk
vaccine was also raised. Otherwise, the company, which is the sole
supplier of vaccines to the MOH, would purchase the imported
finished product directly. Local production of dengue vaccines in
Thailand was considered by most informants to be unlikely in the
foreseeable future.
Data required to inform decision-making about dengue
vaccine introduction
While all countries will require evidence of the safety and
efficacy of any new vaccine before it can be introduced into the
national immunization program, both Sri Lanka and Vietnam
now require that safety and immunogenicity be demonstrated in
the local population through a small Phase I/II study, even for
vaccines pre-qualified by WHO. (An exception is made in
Vietnam for vaccines supplied by the GAVI Alliance. Immuno-
genicity studies are also not required in Vietnam for vaccines that
have been licensed in other countries for five years or more.)
Health policymakers in Sri Lanka, Thailand and Mexico
expressed strong interest in conducting Phase IV post-marketing
surveillance (PMS) studies once the vaccine has been introduced
into the national immunization program to further monitor its
safety. A vaccine researcher in Thailand also recommended using
PMS to track the effects of vaccine introduction on individuals
previously exposed to dengue, while Indian health officials
expressed interest in studying the vaccine’s tolerability in HIV
positive individuals.
Several countries would require additional evidence of disease
burden from different parts of the country before making a
decision to introduce a dengue vaccine. Additional surveillance
data would help to strengthen the case made to policymakers for
dengue vaccination, and in countries, such as India, Colombia and
Mexico, where targeted vaccination is likely, it would help
determine which areas to prioritize for vaccination. The need
for additional disease burden data for decision-making was
mentioned less often in countries confident in their surveillance
and reporting systems or where nation-wide vaccine introduction
is assumed (e.g., Sri Lanka and Thailand).
Economic data were mentioned as critical evidence needed for
policy decisions in all countries. According to health officials in
India, cost-effectiveness estimates are increasingly important to the
government, especially for newer, more expensive vaccines and
‘‘niche’’ vaccines. In Vietnam, informants reported that the
Finance Ministry will only approve financing for imported
vaccines if they are determined to be cost-effective. Also viewed
as critical in various countries – both as stand-alone evidence and
as data needed for the cost-effectiveness analyses – were data on
the cost of the disease in their country, including the cost of
treatment and hospitalization, the cost of vector control, and the
economic impact of the illness on the poor.
Discussion
Summary of findings and implications
The views of policymakers and other stakeholders concerning
dengue and dengue vaccines were first surveyed in 2002 in a study
of four Southeast Asian countries (Cambodia, Indonesia, Philip-
pines and Vietnam) [14]. This new survey of eight countries in
both Asia and Latin America confirms the generally high level of
importance accorded to dengue by government policymakers and
other stakeholders across dengue-endemic countries that was
found in the 2002 study, as well as strong interest in dengue
vaccines for public health use. There were few clear distinctions
found in the views about dengue and dengue vaccines between
Asian stakeholders and those in the Americas. One of the only
discernible differences was the greater interest in vaccinating
adults in the Americas compared to Asia, due to the older age
distribution of disease in the Americas.
As in the 2002 survey, the perceived importance of the disease
and the perceived need to have more effective tools to control it
are driven by the fact that dengue is increasing in incidence and
spreading within countries. Adding to the sense of urgency since
the 2002 study is the fact that major outbreaks are becoming an
annual occurrence in several Asian countries and thus, the disease
is transforming from an epidemic to an endemic or even hyper-
endemic disease. While dengue appears to be worsening in
magnitude and severity, substantial progress has been made in
recent years in controlling such high priority diseases as
tuberculosis, malaria and measles in many dengue-endemic
countries, effectively increasing the relative importance of dengue.
Another key factor contributing to the sense of priority of
dengue and interest in dengue vaccines is the highly visible nature
of the disease. A large part of this visibility is due to the fact that it
often occurs in epidemics – which attract media attention, stoke
fear and even panic in the public, can overwhelm hospitals, and
put a strain on municipal budgets. This is in contrast to non-
epidemic diseases, such as diarrheal disease and pneumonia, which
exact a higher toll than dengue in terms of morbidity and mortality
in many countries, but which attract less public or media attention.
The importance of an epidemic disease pattern in creating a
demand for a vaccine is demonstrated by the high priority that
governments in the meningitis belt of Africa placed on the
development of an effective vaccine against meningococcal
meningitis A – which is now being used in mass campaigns in
several countries – despite the relatively low death toll from the
disease [15,16]. Dengue’s visibility is further enhanced by its
occurrence in cities – which are the centers of the media and
political leadership – and the fact that it strikes all social classes
and not just the poor.
These factors have created considerable political pressure on
governments to control the disease, and according to informants,
will create pressure to introduce a dengue vaccine once one is
available. Recent studies into factors influencing government
adoption of vaccines suggest that political pressure – often fueled
by public fear or anxiety about a disease – has contributed to
decisions to introduce certain new vaccines, even in the absence of
solid disease burden or cost-effectiveness data [17–19]. Political
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considerations were paramount in the rapid introduction of HPV
vaccines in seven developed countries, despite uncertainty about
the vaccines’ long-term effectiveness and the lack of country-
specific cost-effectiveness data in four of the countries [18]. In
some countries, decisions to fund the HPV vaccine bypassed the
normal decision-making process and were even made in the
context of current or upcoming elections. And in the Netherlands,
the government decided to introduce meningococcal C vaccine
without a favorable cost-effectiveness analysis, in part to assuage
public anxiety about the disease [19]. While these examples are
from developed countries, this survey strongly suggests that similar
pressures will be applied to dengue vaccines in many dengue-
endemic developing countries.
The findings of this and the 2002 survey also highlight the
differences in how policymakers and opinion leaders in many
endemic countries define disease burden as compared to global
institutions and donors. While international organizations tend to
define the burden of disease in terms of mortality and morbidity,
and thus consider dengue a low-mortality disease of low priority,
many of those dealing with the disease in endemic countries take a
much more comprehensive view of the dengue disease burden.
They also take into consideration the economic costs of outbreaks
on health systems, the cost of vector control, as well as such
immeasurable, more ‘‘political’’ variables as the panic that
outbreaks can cause among the public; the fear among doctors
of patients deteriorating rapidly due to the unpredictable nature of
the disease; and the demand from parents, the media and society
at large for the government to prevent and control the disease.
Since country-level policymakers must consider all of these factors,
they tend to accord a higher priority to dengue than do global
institutions at present.
Research activities and other factors that will facilitate
the introduction of dengue vaccines
The findings of this survey provide a blueprint for research and
other activities that are needed to accelerate dengue vaccine
introduction in public sector immunization programs in endemic
countries. Primary among the research needs are more systematic
assessments of the local dengue disease burden (e.g., sentinel site
surveillance). Many countries will also require locally-generated
data on the cost of dengue, including cost-of-illness and vector
control costs, and on the cost-effectiveness of vaccination. Studies
to demonstrate the safety and immunogenicity of the vaccine in
the local population will also need to be undertaken in countries
with an explicit policy requiring such studies for new vaccines (e.g.,
Vietnam and Sri Lanka), and perhaps in other countries as well,
given the unique safety concerns about dengue vaccines. Pilot
introduction or vaccine demonstration projects may be the
preferred route to making a decision about vaccine introduction,
as mentioned by informants in several countries and as shown in
the literature to be an important factor in the introduction of
hepatitis B vaccine in some early adopter countries (e.g., Thailand,
Taiwan, Indonesia) [17].
The development of international recommendations, such as by
the WHO Strategic Advisory Group of Experts (SAGE) on
immunization, could also accelerate dengue vaccine introduction.
Not only was this mentioned as an important factor in several
countries in the study, the history of the introduction of
Haemophilus influenzae Type b (Hib) vaccine suggests that the
development of stronger recommendations by WHO in 2006
calling for universal use of the vaccine was a contributing factor to
the rapid adoption of the vaccine, along with intensive advocacy
and GAVI support in the years following the new recommenda-
tions [20].
Three additional conditions or criteria could be critical to the
introduction of dengue vaccines in developing countries. One is
vaccine prices that countries consider ‘‘affordable’’. Dengue vaccine
introduction will likely be aided in the Americas if the vaccine can
be purchased through the PAHO Revolving Fund, which obtains
lower prices than countries can generally obtain on their own.
Second, donor financing, especially through the GAVI Alliance, will
be critical to avoid long delays in vaccine introduction in many low-
and lower-middle income endemic countries. GAVI eligibility
shortened the time for countries to decide to introduce Hib vaccine
by 63% and made up for differences in income levels between
countries [21]. Finally, according to informants in several countries,
policymakers will be more inclined to introduce a dengue vaccine if
it can be incorporated into the countries’ childhood immunization
schedules.
Study limitations
There are a number of limitations of this study that must be
considered. First, the countries included in the study were a
convenience sample and not necessarily representative of all
dengue-endemic countries or of all potential early adopters of
dengue vaccines. Since this study represents only a subset of
potential early adopters of the vaccine, additional studies in other
countries would be of value. Nonetheless, the combined popula-
tion of these eight countries makes up a significant portion of the
global population at risk for dengue, including the largest country
in each region with a substantial dengue burden (India and Brazil).
Secondly, the sample of informants may not have included all
major stakeholders in each country or have been representative of
all stakeholders, since the sample size per country was quite small
and certain key sectors, such as finance ministries, were often not
available for interviews. In addition, by the time dengue vaccines
become available, many of the major decision-makers and opinion
leaders may have changed. Nonetheless, those interviewed in each
country included representatives of groups found in the literature
to be highly influential in the adoption of new vaccines, including
senior Ministry of Health officials, NITAG members, officials from
medical professional societies, leading academicians, and local
vaccine producers [17,22,23].
There is also the possibility that informants’ responses were
biased towards playing up the importance of dengue and interest
in dengue vaccines, since they were aware that the survey was
being conducted by a dengue vaccine project. However, a number
of respondents expressed less concern about dengue or were
hesitant to embrace dengue vaccines, suggesting an atmosphere of
free expression. As with all qualitative studies with open-ended
responses, there is also the possibility of misunderstanding or
biased interpretation of informant’s responses. The structure of the
interviews, which allowed for probing and clarification of
responses, was designed to minimize misinterpretation. Bias could
also arise in the selection of responses to report in the paper,
although efforts were made in the analysis to find and examine
opposing views within a country. However, many responses,
especially those concerning the importance of dengue and interest
in a vaccine, occurred repeatedly across respondents and across
countries and are thus likely to transcend these possible biases and
reflect the prevailing views of stakeholders concerning dengue and
dengue vaccines in these eight countries.
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